Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline
Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but Wall Street wants proof of a turnaround.
Topic
Novo Nordisk
Topic
Novo Nordisk
Lilly Claims 70% of 700,000 New Medicare GLP-1 Seniors
Eli Lilly CEO Dave Ricks says 700,000 seniors started GLP-1s since July's Medicare coverage launch — and 70% of them are on Lilly…
Eli Lilly Says One-Third of New GLP-1 Pill Patients Choose Foundayo
One-third of new GLP-1 pill patients pick Foundayo, CEO Dave Ricks says, as Lilly breaks ground on a $6.5 billion Houston plant d…